Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Portal Monaco.
Press releases published on April 1, 2025
Verifone Receives $235M Equity Investment and Successfully Extends Debt Maturities
GlobeNewswire
·
April 1, 2025
NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Verifone, a global leader in payment and commerce solutions, today announced a $235 million capital investment from Francisco Partners, British Columbia Investment Management Corporation (BCI), and other …
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
GlobeNewswire
·
April 1, 2025
MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of …
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 1, 2025
ALPHARETTA, Ga., April 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George …
Kraig Biocraft Laboratories Secures Four Registered Trademarks for SpydaSilk® Brand, to Advance Commercialization Strategy for Recombinant Spider Silk
GlobeNewswire
·
April 1, 2025
ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or the "Company"), a world leader in recombinant spider silk technology, today announced that it has secured four registered trademarks for …
SynOx Therapeutics Announces Board Chair Transition to Align with Advancing Regulatory and Commercialization Strategy
GlobeNewswire
·
April 1, 2025
Newly Appointed Board Chair, Philip Astley-Sparke, Brings Transatlantic Late-Stage Development, Regulatory and Commercial Expertise Strengthened Leadership and Expanded U.S. Presence Positions SynOx for Regulatory Filings and Commercialization of …
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 1, 2025
FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to …
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
GlobeNewswire
·
April 1, 2025
DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the out- …
Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists
GlobeNewswire
·
April 1, 2025
Appointment of seven recognized experts is validating for Ventyx’s NLRP3 Program -- AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson’s disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) …
Combatting Cyber Threats with AI: Darktrace and Climb Channel Solutions Sign Distribution Agreement for North America
GlobeNewswire
·
April 1, 2025
EATONTOWN, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB) today announced a new partnership with Darktrace, a …
Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation
GlobeNewswire
·
April 1, 2025
New REVEAL-1 study results show early signs of weight maintenance after GLP-1 discontinuation REMAIN-1 pivotal study now more than 50% enrolled; midpoint data analysis anticipated in Q3 2025 BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Fractyl …
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study
GlobeNewswire
·
April 1, 2025
MINDFuL Phase II Blinded, Randomized, Placebo-Controlled Data Anticipated June 2025 Boca Raton, Florida, April 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on …
3D Systems Completes Sale of Geomagic Software Portfolio
GlobeNewswire
·
April 1, 2025
Closed transaction for $123 million, with expected net proceeds of approximately $100 million to strengthen balance sheet and invest in future growth and profitability initiatives Sharpens focus on core additive manufacturing software solutions — 3D Sprint …
Medicenna to Present at Jones Healthcare and Technology Innovation Conference
GlobeNewswire
·
April 1, 2025
TORONTO and HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune …
Codexis Appoints Cynthia Collins to Board of Directors
GlobeNewswire
·
April 1, 2025
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Cynthia Collins to the Company’s …
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)
GlobeNewswire
·
April 1, 2025
Results support continued development in MDD with concomitant EDS; Phase 3 trial planned in 2025 Approximately 50 percent of MDD patients experience EDS1, highlighting high unmet need NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. ( …
Trust Stamp files its 2024 10-K and gives forward-looking revenue and expense guidance
GlobeNewswire
·
April 1, 2025
Atlanta, GA, April 01, 2025 (GLOBE NEWSWIRE) -- Trust Stamp announces that: It filed its 10-K report for the 2024 Financial Year after the Nasdaq market closed on March 31st, 2025. Q4 2024 Revenue was $1.50m increased from $0.51m for Q3 of 2024 and $0.58m …
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
GlobeNewswire
·
April 1, 2025
WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of …
CGS Immersive Unveils 2025 Operational Excellence Outlook Report: Embracing Emerging Technology Critical to Future-Proofing Businesses
GlobeNewswire
·
April 1, 2025
NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- CGS Immersive™, the leader in enterprise learning that is modernizing training and development with AI and XR technologies, today released its 2025 Operational Excellence Report. The report highlights how AI, …
Lantronix Names Tech Industry Veteran Todd Rychecky General Manager and Head of Out-of-Band Management Business
GlobeNewswire
·
April 1, 2025
IRVINE, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for IoT solutions enabling Edge AI Intelligence, today announced the appointment of Todd Rychecky as general manager and head of …
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
GlobeNewswire
·
April 1, 2025
PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation …